VAERS Explorer
Back to explore

Report #2831774

Received Mar 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
MD
Recovered
Not recovered
Vaccinated
Feb 21, 2025
Onset
Feb 1, 2025
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALSUNKUNKLA

Symptoms (8)

ChillsFatigueHeadacheInjection site erythemaInjection site indurationInjection site swellingInjection site warmthPyrexia

Symptom narrative

raised bump that is red, 4 inches from injection site, size of a thumb; raised bump that is red and hot to touch, 4 inches from injection site, size of a thumb; Swelling of injection site; hardening injection site; Fever; Headache; Fatigue; Chills; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site swelling in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 21-FEB-2025, the patient received Shingrix (left deltoid) .5 ml. In FEB-2025, less than a week after receiving Shingrix, the patient experienced chills (Verbatim: Chills). On 22-FEB-2025, the patient experienced injection site swelling (Verbatim: Swelling of injection site), injection site induration (Verbatim: hardening injection site), fever (Verbatim: Fever), headache (Verbatim: Headache) and fatigue (Verbatim: Fatigue). On 28-FEB-2025, the patient experienced raised rash (Verbatim: raised bump that is red, 4 inches from injection site, size of a thumb) and feeling hot (Verbatim: raised bump that is red and hot to touch, 4 inches from injection site, size of a thumb). The patient was treated with cetirizine hydrochloride (Zyrtec) and ibuprofen. On 25-FEB-2025, the outcome of the injection site swelling, fever, headache, fatigue and chills were resolved and the outcome of the injection site induration was resolved (duration 3 days). The outcome of the raised rash and feeling hot were not resolved. The reporter considered the injection site swelling, injection site induration, fever, headache, fatigue, chills, raised rash and feeling hot to be related to Shingrix. The company considered the injection site swelling, injection site induration, fever, headache, fatigue, chills, raised rash and feeling hot to be related to Shingrix. Additional Information: GSK Receipt Date: 07-MAR-2025 Reporter was a pharmacist reporting for herself.